Home / Themes / GLP-1 Short '24: Weight Loss Plans
GLP-1 Short '24: Weight Loss Plans
Last updated
Theme thesis · 2/5 sections · Tickers 0 with notes · 9 pending
Bull / Bear Details has the investment thesis and bull/bear points. Overview is monitoring guidance (hiring, forums, second-order trends, search keywords, Google Trends, datasets).
Bull / Bear DetailsAs of Spring 2025, the thesis for GLP-1 '24: Weight Loss Plans is bearish. The widespread adoption of GLP-1 drugs for weight loss has significantly impacted the
Thesis
As of Spring 2025, the thesis for GLP-1 '24: Weight Loss Plans is bearish. The widespread adoption of GLP-1 drugs for weight loss has significantly impacted the demand for traditional weight loss plans and supplements offered by companies like Herbalife (HLF) and Medifast (MED). Despite efforts to adapt, these companies face declining revenues due to changing consumer preferences and the pharmaceutical advancements in weight management.
Bull case
GLP-1 drugs have proven highly effective for weight loss, reducing the need for traditional diet plans and supplements.
Consumer preferences have shifted towards pharmaceutical solutions, as seen in declining sales for HLF and MED.
Insurance coverage for GLP-1 drugs is expanding, making them more accessible and further decreasing the attractiveness of traditional weight loss programs.
Bear case
Some consumers may still prefer natural weight loss methods, maintaining a niche market for HLF and MED.
Potential long-term side effects of GLP-1 drugs could lead to renewed interest in traditional weight loss plans.
Regulatory changes or pricing pressures could impact the affordability and accessibility of GLP-1 drugs, benefiting traditional weight loss companies.
Key Metrics
| Metric | Cadence | What It Signals | Update Source |
|---|---|---|---|
| HLF and MED quarterly sales | Quarterly | Financial health and consumer demand | Google_Sheets |
| Consumer health trend surveys | Quarterly | Shifts in consumer preferences | Google_Sheets |
| GLP-1 prescription volumes | Monthly | Adoption rate of pharmaceutical solutions | Google_Sheets |
Constituents
- BODIT3· no notes yet
- FTLFT3· no notes yet
- HLFT3· no notes yet
- LFVNT3· no notes yet
- LIMXT3· no notes yet
- MEDT3· no notes yet
- NHTCT3· no notes yet
- NUST3· no notes yet
- USNAT3· no notes yet